ReviewCells2020
Advances and Prospects in Vaccine Development against Enterococci.
Review in Cells, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed.
- Cross-Sector Antimicrobial Resistance and Virulence inAntibiotics (Basel, Switzerland) · 2026Article
- Taming Superbugs: Current Progress and Challenges in Combating ESKAPE Pathogens.Pathogens (Basel, Switzerland) · 2025Review
- The Central Importance of Vaccines to Mitigate the Threat of Antibiotic-Resistant Bacterial Pathogens.Vaccines · 2025Review
- A Self-Assembling Cross-Protective Antigen Against Multiple Gram-Positive Nosocomial Pathogens.ACS omega · 2025Article
- Insights into ecology, pathogenesis, and biofilm formation ofMicrobiology and molecular biology reviews : MMBR · 2025Review
- Unveiling the wonders of bacteria-derived extracellular vesicles: From fundamental functions to beneficial applications.Heliyon · 2025Review
- Resistance to last-resort antibiotics in enterococci.FEMS microbiology reviews · 2025Review
- Article
- Enterococcus faecium: evolution, adaptation, pathogenesis and emerging therapeutics.Nature reviews. Microbiology · 2024Review
- Infection Prevention and Control Strategies According to the Type of Multidrug-Resistant Bacteria andAntibiotics (Basel, Switzerland) · 2024Review
- A rationally designed antigen elicits protective antibodies against multiple nosocomial Gram-positive pathogens.NPJ vaccines · 2024Article
- Investigation of cross-opsonic effect leads to the discovery of PPIase-domain containing protein vaccine candidate to prevent infections by Gram-positive ESKAPE pathogens.BMC microbiology · 2024Article
- Putative new combination vaccine candidates identified by reverse vaccinology and genomic approaches to control enteric pathogens.BMC immunology · 2024Article
- The Impact ofPathogens (Basel, Switzerland) · 2024Review
- Trivalent immunization with metal-binding proteins confers protection against enterococci in a mouse infection model.FEMS microbes · 2024Article
- Pheromone cCF10 inhibits the antibiotic persistence ofFrontiers in microbiology · 2024Article
- Enterococcal Membrane Vesicles as Vaccine Candidates.International journal of molecular sciences · 2023Article
- Vancomycin Resistance inMicroorganisms · 2022Review
- Article
- Designing a novel multi-epitope vaccine to evoke a robust immune response against pathogenic multidrug-resistant Enterococcus faecium bacterium.Gut pathogens · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Enterococci are the second most common Gram-positive pathogen responsible for nosocomial infections. Due to the limited number of new antibiotics that reach the medical practice and the resistance of enterococci to the current antibiotic options, passive and active immunotherapies have emerged as a potential prevention and/or treatment strategy against this opportunistic pathogen. In this review, we explore the pathogenicity of these bacteria and their interaction with the host immune response. We provide an overview of the capsular polysaccharides and surface-associated proteins that have been described as potential antigens in anti-enterococcal vaccine formulations. In addition, we describe the current status in vaccine development against enterococci and address the importance and the current advances toward the development of well-defined vaccines with broad coverage against enterococci.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.